Meeting Reports

2023

The 38^th Annual Meeting of the Japanese Society for Psoriasis Research (JSPR)

Reporter

TOKUYMA Michio, M.D. (Department of Dermatology, School of Medicine, Tokai University, JAPAN and The Director and the Secretary in JAPAN of the ASP)
MABUCHI Tomotaka, M.D. & Ph.D. (Department of Dermatology, School of Medicine, Tokai University, JAPAN and The Vice President, Secretary General of the ASP)

The 38^th Annual Meeting of the Japanese Society for Psoriasis Research was held in a hybrid format from August 25th to 26th at the Grand Nikko Tokyo Odaiba in Japan.

This event featured on-site and partial real-time live streaming, drawing approximately 1,230 registered participants (around 1,050 attendees on-site), including dermatologists and scientists from Japan and abroad. The conference covered intriguing topics in both Japanese and English sessions.

The theme of the academic conference was "Breakthrough psoriasis practice －aiming for international harmonization－" It aimed to illuminate the differences in disease interpretation between domestic and international perspectives, foster mutual understanding, and take a step towards international cooperation. The event featured educational lectures and symposiums with invited international speakers.

During the educational lectures, discussions revolved around the pathogenesis of neutrophil-related skin diseases, pyoderma gangrenosum, and psoriasis-related conditions such as palmoplantar pustulosis (PPP). Differences in disease concepts between Japan and other countries were explored.

In the symposiums, topics included the relationship between lesion infections in psoriasis and palmoplantar pustulosis, gut bacteria connecting skin and the intestines, depression, and the relationship between the microbiome and psoriasis. Lectures were given by professionals from various fields, including gastroenterology, psychiatry, and dentistry. For the rare disease generalized pustular psoriasis (GPP), doctors from Japan, the United States, Europe, and Malaysia highlighted the distinctive features of diagnosis and treatment in their respective countries.

A total of 131 general presentations were made. These covered trends in psoriasis treatment based on epidemiological surveys conducted by the Japanese Society for Psoriasis Research, regional aspects of psoriatic arthritis, surveys conducted by different facilities, characteristics of patients with malignant tumor complications, and the treatment of psoriasis patients with comorbidities. Statistical analyses of palmoplantar pustulosis were also presented.

In clinical trials, the effectiveness and safety of treatments like broadleaf for palmoplantar pustulosis patients, as well as evaluations of drugs like deucravacitinib, Upadacitinib, and spesolimab, were reported.
In basic research, there were presentations on the potential involvement of antigen-presenting cells expressing macrophage galactose-type C-type lectin in psoriasis and reports on how topical imatinib inhibits vascular remodeling and improves psoriasis-like skin rashes in imiquimod-induced mouse models.

The 26^th Annual Meeting of the Korean Society for Psoriasis & Asian Summit for Psoriasis 2023

Reporter

KIM Byungsoo, M.D. & Ph.D. (Professor and Chair of Department of Dermatology, Pusan National University School of Medicine, Pusan, KOREA ; The Secretary General of the Korean Society for Psoriasis and The Secretary (in Korea) & Director of the Asian Society for Psoriasis)

Photo Album of the 26 the Annual Meeting of the & Asian Summit for Psoriasis 2023 was　edited by Dr. JO Seong Jin, Director of Academic Affair of KSP, Seoul National University.
Photo Album

2021

The 6^th Psoriasis Treatment Seminar for Dermatologists

Reporter

SONG Hae Jun, M.D. & Ph.D.(The Vice President of the ASP)

The 35^th Annual Meeting of the JSPR (Japanese Society for Psoriasis Research)

Reporter

TOKUYMA Michio, M.D. (The Director and the Secretary in JAPAN of the ASP)
MABUCHI Tomotaka, M.D. & Ph.D. (The Vice President of the ASP)

The 36^th Annual Meeting of the Japanese Society for Psoriasis Research was held in forms of virtual and onsite because of COVID-19 from 3 September to 4 September 2021 in Tokyo Disney Sea･Hotel Miracosta, Japan.
As for general presentations, 133 papers were presented, and about 1,000 dermatologists and scientists from Japan, China, Korea, Taiwan, and other countries participated including online and interesting topics were presented.
In general presentations, there were many such topics as safety and efficacy of new treatments and case reports of psoriasis associated with treatments and other diseases. New treatments included IL23 inhibitors (Risankizumab, Tildrakizumab), TNFα inhibitor (Sertorizumab pegol), IL17 inhibitor (Bimenkizumab), IL36 inhibitor (Spesolimab), Tyk2 inhibitor (Deucravacitinib), and JAK inhibitor (Upatatinib).
Case reports of psoriasis associated with treatments and other disease including interstitial pneumonia, tuberculosis, COVID-19, bullous pemphigoid, and internal malignancy were presented.
Asian Psoriasis Forum was held chaired by Prof. IKEDA Shigaku, who is a professor of Department of Dermatology, Juntendo University and Prof. MABUCHI Tomotaka who is a professor of Department of Dermatology, Tokai University. Dr.SHAO Shuai, who is Department of Dermatology, Xijing Hospital, Fourth Military Medical University Xiʼan, China, Dr.KIM Tae-Gyun, who is Department of Dermatology, Severance Hospital Cutaneous Biology Research Institute Yonsei University College of Medicine, Seoul, Republic of Korea, and Dr.LIAO Chang, who is Department of Dermatology, National Taiwan University Hospital, Taiwan lectured "Neutrophils in psoriasis", "Revisiting IL-23-dependent psoriasis pathogenesis via a single-cell transcriptome approach", and "Psoriasis, early intervention, less comorbidities?, long remission? " respectively.

Tokyo Disneyland 20^th Anniversary Event

The 24^th Annual Meeting of the KSP (Korean Society for Psoriasis)

Reporter

BYUN Ji Yeon, M.D. & Ph.D. (The Director of International Relations of the KSP)
CHOE Yong Beom, M.D. & Ph.D. [The Secretary in Korea of the ASP]

Even though it had been challenging to organize a meeting during the Covid-19 pandemic and only limited number of attendees were allowed due to the national CDC regulations on gatherings, many enthusiastic participants attended. Attendees were able to have eager discussions and share meaningful insights more than any other time.
This year, we had distinguished lectures, which were "Future paradigm in psoriasis treatment, from small molecules to biologics" by Dr Mark Lebwohl (Mount Sinai, USA) and "Lymph node-fibroblast reticular cells regulate differentiation of CD4+ T helper cells through CD25" by Dr. Seung-Hyo Lee (KAIST, Korea). In addition, we had two educational lectures, which were timely COVID-19-related, "Psoriatic disease and COVID-19" by Dr. Ronald Vender (McMaster University, Canada) and "Managing psoriasis during the COVID-19 pandemic and vaccination" by Dr Dong Hyun Kim (CHA University, Korea). These most definitely helped further understanding of the management of psoriasis during this pandemic. Moreover, results from latest research were shared and discussed in the free communication sessions. In the session of "Voice from the KSP", guidelines for the reimbursement of psoriasis treatment, which is an important issue in the management of psoriatic patients in Korea, were lectured to offer detailed information which can be easily overlooked without attention.

The 7^th Tongji University Psoriasis Summit Forum

Reporter

SHI Yuling Shi, M.D. & Ph.D. (The Director of the ASP)

This academic conference brought together well-known experts and scholars to discuss the latest progress in clinical research and basic research of inflammatory skin diseases such as psoriasis and atopic dermatitis.
In this forum, the experts shared the latest research progress of psoriasis and this forum also benefited the clinicians a lot. This forum established a zero-distance contact between scholars studying in dermatology.
We will continue host the 8th Psoriasis Summit Forum on 18th-20th November, 2022.

The 5^th China Psoriasis Congress (CPC)

https://mail.qq.com/cgi-bin/ftnExs_download?k=bd316262070da49cef29fd471739514c5d530053015b0007140903535014570608504f5a035b074e01065553020a02055b015b0731766356545407165857043c4b54120d434d10510903534f614b06104a1110075d5c02105c110d04114d0b0619770b044551432051580c07425c43334a5e100b504a0a1019720d0c564b06104a1f060d5241635e&t=exs_ftn_download&code=91bb19cc

Reporter

FAN Pingshen, M.D. & Ph.D. (The Director and the Secretary in China of the ASP)
WANG Gang, M.D. & Ph.D.(The Vice President of the ASP)

From the afternoon of 28 October to 30 October 2021, the 5^th China Psoriasis Congress was successfully held in forms of online and onsite in Hefei, China. 60 experts in basic research and clinical treatment of psoriasis from home and abroad gave informative presentations on the latest advances in the field of psoriasis.
Honorary President of the Asian Psoriasis Society (ASP), Prof. ZHENG Min, Special Advisor Prof. ZHANG Xuejun, Vice President Prof. WANG Gang, board members Prof. CHEN Xiang, Prof. JIN Hongzhong, Prof. SHI Yuling, Prof. WANG Honglin, Prof. ZHANG Xibao and Prof. MAN Xiaoyong attended the conference and gave special speeches.
Based on the foundation and clinical practice while aiming at the frontier progress, the forum covered a wide range of topics, including basic research on psoriasis, clinical experience with conventional and new medications, rational selection of biological agents, side effects of drugs, psoriasis co-morbidities, interpretation of psoriasis guidelines, patient education and popular science, disease management and nursing, Traditional Chinese Medicine therapies, COVID-19 impact to bio-antibody treatment, special types of psoriasis, advances in diagnosis and treatment, translational research in dermatology, multidisciplinary experience brought to dermatology and other aspects.

The 9^th Symposium for Biologics

Reporter

SONG Hae Jun, M.D. & Ph.D.(The Vice President of the ASP)

2020

The 2020 ASP Forum & Cosentyx grand Ceremony

The 2020 ASP Forum & Cosentyx grand Ceremony

2019

The Cosentyx Annual Meeting 2019

The Cosentyx Annual Meeting 2019

The 23^rd Annual Meeting of the Korean Society for Psoriasis

Reporter
JO Seongjin, M.D. & Ph.D. (The Director of the ASP)
SONG Hae Jun, M.D. & Ph.D. (The Vice President of the ASP)

　The Korean Society for Psoriasis was established in 1997 to promote research activities and to improve the quality of management for patients with psoriasis in Korea. During past years, the KSP make various commitments and play pivotal role to encourage research activity, to provide education for dermatologists and patients, and to improve public awareness on psoriasis.
　The KSP is also communicating and sharing expertise and friendship with other societies/researchers studying on psoriasis.
In this year, distinguished lectures were presented, including "The latest updates on the optimal topical treatment of psoriasis" by Dr. Sascha Gerdes (University of Medical Center Schleswig-Holstein, German), "The role of biological therapy in the new era" by pf. Giampero Girolomoni, and "New novel biologics for complete clearance" by pr. Kim Papp.

The 34^th Annual Meeting of the Japanese Society for Psoriasis Research

Reporter
TOKUYAMA Michio, M.D. (The Directoe and the Secretary in Japan of the ASP)
MABUCHI Tomotaka, M.D. (The Vice President of the ASP)

　In recent years, research on the pathology of psoriasis has made tremendous progress, and the newly developed treatments have produced amazing effects that could not have been imagined 30 years before.
　However, on the other hand, there is a fact that DLQI of patients who have achieved PASI clearance with biologics is not always zero. Thinking deeply in the heart of psoriasis patients is essential for those involved in psoriasis medical care and research. In addition, as the word "Drugs don't work in patients who don't take them," no matter how effective the drug, care must be taken to improve treatment adherence. Of course, dealing with complications and giving consideration to the social life of patients are also important. While thinking about the program of this society, I became aware of the importance of conducting psoriasis more broadly, deeper and more kindly than just examining the surface of the skin. "Beyond the Skin Surface".
　As for general presentations, 170 presentations were presented, and about 1,000 dermatologists and scientists from Japan, the United States, China, Korea, Taiwan, Thailand, and other countries participated.
　In the president's special plan, Prof. Otsuki who is the president of JSPR gave a lecture on the history of MTX approved in Japan in 2018.
　In the special lecture, Dr. Uwe who is a professor of Department of Dermatology and Clinic of Psychosomatic Medicine and Psychotherapy, Justus-Liebig-University of Giessen lectured psoriasis and burden of disease, Dr. Andreas who is a professor of Department of Dermatology and Allergology Ludwig-Maximilian University lectured treatment adherence in chronic inflammatory skin disease.
　At the symposium, psoriasis in children, the aim of improving adherence in psoriasis treatment, and PAO and SAPHO syndrome were lectured.
　At the educational lectures, control of immunity and inflammation by sympathetic nerves, pathology of psoriasis, psoriasis and itching, elucidation of the pathogenesis of psoriasis and genomic drug discovery using genetic statistics, and focal infections such as palmoplantar pustulosis were lectured.
　In general presentations, there were many such topics as biologics including anti-IL17 monoclonal antibody, anti-IL17 receptor monoclonal antibody, anti-IL23 monoclonal antibody, their adverse events, and apremilast.
　This year's topic was that guselkumab has been adapted for palmoplantar pustulosis in Japan. Many presentations on palmoplantar pustulosis and palmoplantar pustulotic arthro-osteitis were presented
　In Asian Psoriasis Forum, Prof. Mabuchi who is a professor of Department of Dermatology, Tokai University, Prof. Yamanaka who is a professor of Department of Dermatology, Mie University, Dr. Sindhvananda who is a senior advisor to CICM, Thammasat University, Dr. Fan who is an associate professor, Department of Dermatology Xijing Hospital, Fourth Military Medical University, Dr. Dino Tsai who is a head of Psoriasis Clinic, Department of Dermatology, Dianthus Medical Group/ Taiwan Adventist Hospital/ Dr. Huang Dermatological Clinic, and Prof. Shin who is a professor of Department of Dermatology, Chosun University lectured each countrie's psoriasis epidemiology, genetic and environmental factor, treatment, public health insurance, and so on.

The 4^th Xi'an International Psoriasis Forum

Reporter
FAN Pingshen, M.D. & Ph.D. (The Director and the Secretary in China of the ASP)

　The Fourth Xi'an International Psoriasis Forum co-organized by Department of Dermatology at Xijing Hospital and a marketing team of LEO Pharma was held in Xi'an on August 24, 2019.
　This forum invited 16 renowned experts of psoriasis research from home and abroad, to present their work in a broad range of topics, including pathogenesis, therapeutic strategy, patient management, and etc. "Skin disorders mediated by T cells" reported by Prof. Thomas S. Kupper and "Treatment of psoriasis during pregnancy" reported by Prof. Mariko SEISHIMA and others speeches were warmly responded and highly recognized by participants. The forum received 210+ psoriasis experts on site and was also watched by 1,400+ audiences online.
　Thanks to the kind guidance of Prof. Gang Wang, Chair of Xijing Dermatology and president-elect of Chinese Dermatologist Association, enthusiastic support and contribution of participating experts, as well as the hard work of LEO pharma, this forum successfully built a good platform for information exchange in psoriasis reach within and between the domestic and international dermatology community, and was highly praised by participants. Leo pharma will make continuous effort to organize such academic events and exchanges, to enable more dermatological practitioners obtain appropriate therapeutic options and bring wellbeing to more psoriatic patients.